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Abstract
Background - This study aimed to determine five-year efficacy of catheter ablation for persistent 
atrial fibrillation (PsAF) using AF termination as a procedural endpoint.
Methods and Results - 150 patients (57±10 years) underwent PsAF ablation using a stepwise 
ablation approach (pulmonary vein isolation, electrogram-guided and linear ablation) with the 
desired procedural endpoint being AF termination. Repeat ablation was performed for recurrent 
AF or atrial tachycardia (AT). AF was terminated by ablation in 120 patients (80%). Arrhythmia-
free survival rates after a single procedure were 35.3±3.9%, 28.0±3.7%, and 16.8±3.2% at 1, 2, 
and 5 years, respectively. Arrhythmia-free survival rates after the last procedure (mean 2.1±1.0 
procedures) were 89.7±2.5%, 79.8±3.4%, and 62.9±4.5%, at 1, 2, and 5 years, respectively. 
During a median follow-up of 58 (IQR 43-73) months following the last ablation procedure, 97 
of 150 (64.7%) patients remained in sinus rhythm without antiarrhythmic drugs (AADs).  
Another 14 (9.3%) patients maintained sinus rhythm after re-initiation of AADs, and an 
additional 15 (10.0%) patients regressed to paroxysmal recurrences only. Failure to terminate AF 
during the index procedure (HR 3.831; 95%CI: 2.070-7.143; p<0.001), left atrial diameter 
PP+5&,-S FRQWLQXRXV$)GXUDWLRQPRQWKV+5
1.984; 95%CI: 1.024-3.846; p<0.04) and structural heart disease (HR 1.874; 95% CI: 1.037-
3.388; p=0.04) predicted arrhythmia recurrence.
Conclusions - In patients with PsAF, an ablation strategy aiming at AF termination is associated 
with freedom from arrhythmia recurrence in the majority of patients over a 5-year follow up 
period.Procedural AF non-termination and specific baseline factors predict long-term outcome 
after ablation.
Key words: ablation; atrial fibrillation; atrial tachycardia
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Introduction
Catheter ablation is an established treatment option for patients with symptomatic drug refractory 
AF.1 In paroxysmal AF (PAF) ablation, pulmonary vein isolation (PVI) alone is a well-defined 
procedural endpoint.1-3 This strategy, although effective in maintaining sinus rhythm (SR) for 
PAF,3 has limited success in persistent AF (PsAF).1,4-7 The understanding of the substrate 
maintaining persistent AF remains rudimentary. The targets and endpoints of PsAF ablation are 
ill-defined, and there is no consensus on the optimal ablation strategy in these patients. Whether 
termination of AF by ablation is associated with a lower risk of recurrent arrhythmia compared 
to procedural failure to terminate AF with the need for electrical cardioversion remains 
controversial.8-19
 Finally, data on long-WHUPRXWFRPHRI3V$)DEODWLRQ\HDUVLVOLPLWHG6-20 and the 
predictors of arrhythmia recurrence after PsAF ablation are ill-defined.  
 The aims of this prospective observational study were twofold: 1) to determine the five-
year outcome in PsAF patients who underwent a stepwise ablation approach aiming at 
procedural AF termination and 2) to determine whether procedural AF termination and other 
baseline factors impact arrhythmia recurrence during long-term follow-up. 
Methods 
Study Population
The study population comprised 150 consecutive patients undergoing their first catheter ablation 
for persistent AF between November 2003 and October 2007 at our institution. Persistent AF 
was defined as continuous AF sustained beyond seven days. 1,21 Longstanding persistent AF was 
defined as persistent AF >12 months’ duration.1,21 $VIRULQFOXVLRQFULWHULDDWRWDO$)KLVWRU\
PRQWKVDQGDFRQWLQXRXV$)GXUDWLRQPRQWKZHUHUHTXLUHG$OOSDWLHQWVKDGIDLOHGWR
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maintain SR despite cardioversion and/or treaWPHQWZLWK$$'2QO\SDWLHQWVZKRSUHVHQWHG
for the ablation procedure in AF were included. Baseline characteristics are summarized in Table 
1. This study was approved by the institutional review committee of the University of Bordeaux 
Health System, and all patients gave written informed consent.
Electrophysiological Study and Ablation Procedure 
Details of the peri-procedural management and the ablation technique at our institution have 
been described previously,8,9,11,12,21-24 and are described in detail in the online data supplement.
As it is standard clinical practice at our institution, all AADs were discontinued at least five half-
lives prior to ablation except for amiodarone (n=32). All patients received oral anticoagulation
(target INR 2–3) for at least 1 month prior to the procedure. Patients underwent transesophageal 
echocardiography within 48 h of the procedure to rule-out atrial thrombus. Warfarin was 
restarted the day after the procedure for at least six months after each ablation procedure and was 
continued thereafter at the physician’s discretion. 
 In all patients, sequential stepwise ablation was performed in the following order: PVI, 
electrogram-based ablation, and linear ablation.
Circumferential PVI was performed with the endpoint of abolition or dissociation of 
electrical activity of all PVs. When AF did not terminate during PVI, the procedure was 
continued with electrogram-based ablation in the LA. When electrogram-based ablation of the 
LA did not result in organization of the coronary sinus, additional ablation within the coronary 
sinus was performed. Linear ablation was performed if AF persisted following the previous 
ablation steps. A roof line was performed joining the right and left superior PVs, and if AF 
continued, a mitral isthmus line from the mitral annulus to the left inferior PV was performed, 
with the endpoint of abolition of local electrograms. 
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Electrogram-based ablation was continued in the right atrium (RA) if AF did not 
terminate during LA ablation and the RA appendage demonstrated a shorter cycle length than the 
LA appendage. Linear ablation was performed in all patients at the cavotricuspid isthmus either 
before or after restoration of SR and bidirectional conduction block was confirmed.
Procedural Endpoints
The primary procedural endpoint was termination of AF, which was defined as a transition 
directly from AF to SR or from AF to one or more ATs without antiarrhythmic drugs or 
electrical cardioversion. Whenever AF terminated to one or more ATs these were targeted for 
ablation until SR was achieved. When SR had not been restored by ablation, the AT was 
terminated by cardioversion. When AF was not terminated by ablation, SR was restored by 
cardioversion. Once SR was achieved, verification of entrance block of all PVs, and bidirectional 
block along all linear ablations was checked and, if necessary, supplemental ablation was 
performed as required to achieve block. No attempt at arrhythmia reinduction was made.
Repeat procedures were performed targeting the documented recurrent arrhythmia and 
following the same stepwise approach aiming at arrhythmia termination.
Follow Up 
Patients were followed up at our institution 1, 3, 6, and 12 months post-procedure, and every 6 
months thereafter, including 24h Holter monitoring. When patients had been asymptomatic and 
in SR for 12 months, they were followed up at our institution at 6 monthly intervals, including 
24h Holter monitoring. Patients referred from distant regions (n=12) were medically released 12 
months after each procedure for regular follow-up with their local cardiologists as described, and 
every effort was made to update our clinical records with their progress and bi-annual Holter 
reports. Between visits, all patients were encouraged to seek ECGs or Holter monitoring for any 
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symptoms suggestive of AF. The completeness rates for Holter monitoring were 96%, 91%, 
90%, 85%, 83%, 79%, and 91% at 1, 2, 3, 4, 5, 6, and 7 years, respectively. Patients were 
personally contacted for a final follow-up between October 2011 and May 2012, and 7-day 
Holter monitoring (AFT-1000, Holter Supplies, France) was performed after this visit. The 
overall Holter completeness rate throughout the study was 89.7%. 
 AADs were continued for 1–3 months following the ablation procedure. Repeat ablation 
was offered to patients with arrhythmia recurrence following the initial 3-month follow-up 
period. The primary study end point was freedom from any asymptomatic or symptomatic atrial 
tachyarrhythmia lasting >30 s off antiarrhythmic drugs after the last ablation procedure. 
Regression of PsAF was defined as change to PAF or maintenance of SR on AADs.
Statistical Analysis
Continuous variables are presented as mean±SD, or median and interquartile range (IQR,25th-
75th percentiles). Categorical variables are presented as percentages (%) and counts.  Two-group 
comparisons (i.e., with or without AF termination during ablation; with and without amiodarone 
at the time of procedure) of continuous variables were performed by Student t tests if normally 
distributed or with Wilcoxon Rank-Sum tests if the normality assumption was violated according 
to Shapiro-Wilk tests or visual inspection of normal probability plots. Categorical variables were 
compared by Chi-square tests. Baseline (i.e., variables listed in Table 1) and procedural factors 
(i.e., method of AF termination, procedural duration, and RF duration) associated with 
arrhythmia recurrence during following-up were assessed in univariate and multivariable Cox 
proportional hazard models, from which hazard ratios (HR) and 95% confidence intervals (CI) 
were derived, after verification of proportional-hazards assumption by time-dependent 
interactions and goodness-of-fit statistics (weighted Schoenfeld residuals). Factors associated 
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with P-values <0.1 in univariate analyses were included in stepwise multivariate Cox regression 
models.  A receiver-operator characteristic (ROC) curve analysis was performed to determine the 
best cut-off value for the left atrial diameter and for continuous AF duration in predicting 
arrhythmia recurrence following the last ablation procedure.  The value with the greatest 
discriminatory potential was selected on the basis of Youden’s Index. Time to first arrhythmia 
recurrence was calculated and plotted using the Kaplan Meier product-limit method with 
comparisons performed by log-rank statistics. Two-tailed P-values <0.05 were considered to 
indicate statistical significance. Baseline characteristics including age, sex, co-morbidities, and 
pharmacological therapy were complete in all patients.  Echocardiographic data were complete 
in 94%. Missing data were handled by listwise deletion (i.e., complete case analyses). Statistical 
analyses were performed using SPSS 20.0 (IBM, Armonk, New York, USA). 
Results
Index Procedural Data
In 30 of 150 patients (20%) AF required pharmacological and/or DC cardioversion. (Figure 1) 
Of the 120 patients (80%) in whom AF terminated during ablation, 90 terminated via an 
intermediate step of AT and the remaining 30 converted directly from AF to SR. In those who 
terminated AF via AT, 75 patients could be successfully ablated to SR, whereas the remaining 15 
patients required pharmacological and/or DC cardioversion to reach SR. A total number of 
164ATs (1.1±1.1 ATs per patient overall) occurred. 
 Compared to patients without AF termination, patients with AF termination had a shorter 
duration of continuous AF (12 (6-19) months vs. 24 (17-44) months; p<0.001) and a smaller LA 
diameter (47±7 mm vs. 52±8 mm; p<0.01). 
The rate of AF termination was similar in patients with and without amiodarone at the 
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time of the procedure (75% versus 81%, P=0.58). Mean procedural and RF durations for patients 
in whom termination of AF was achieved vs. not achieved were 264±74 min vs. 263±64 min 
(p=0.91), and 89±28 min vs. 99±27 min (p=0.09), respectively. 
Single Procedure Outcome
During a median follow-up of 70 (IQR 60-81) months from the first ablation procedure until the 
last follow-up visit, SR was maintained in 23 of 150 (15.3%) patients following a single 
procedure. Arrhythmia-free survival rates after a single catheter ablation procedure were 
35.3±3.9%, 28.0±3.7%, and 16.8±3.2% at 1, 2, and 5 years, respectively (see online data 
VXSSOHPHQW$UUK\WKPLDUHFXUUHGLQSDWLHQWVZKRKDGPDLQWDLQHG65IRU\HDU,
including 14 (9.3%) patients with recurrences >3 years after ablation. Recurrent arrhythmias 
after the index procedure werePsAF in 42 (33.1%) patients, PAF in 17 (13.5%) patients, and AT 
in 68 (53.5%) of 127 patients. 
 In multivariate analysis, the only factor independently associated with arrhythmia 
recurrence was failure to terminate AF during the index procedure (HR 1.650; 95%CI: 1.086-
2.513; p=0.02; Figure 2).
Multiple Procedure Outcome
109 patients (72.7%) underwent 167 repeat procedures (61 (36.5%) for AF, 106 (63.5%) for AT; 
Figure 3). Recovered PV conduction was found in 96/109 (88.1%) patients. Overall, PVI was 
performed in all 150 patients but was never the sole ablative strategy performed over the course 
of the study. 
 A total of 317 procedures were performed in 150 patients (2.1±1.0; median 2 (IQR 1-3)). 
41 (27.3%) patients had 1 procedure, 66 (44%) had 2, 31 (20.7%) had 3, 10 (6.7%) had 4, 1 
(0.7%) had 5, and 1 (0.7%) patient had 6 procedures. The first and the last redo procedures were 
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performed 11±13 and 19±19 months after the index procedure, respectively. During a median 
follow-up of 58 (IQR43-73) months following the last ablation procedure, 97/150 (64.7%) 
patients remained in SR without AADs, and 111 patients (74%) remained in SR when including 
those on AADs (Amiodarone in 6 patients).Arrhythmia-free survival rates after the last catheter 
ablation procedure and off AADs were 89.7±2.5%, 79.8±3.4%, and 62.9±4.5%, at 1, 2, and 5 
years of follow-up, respectively (Figure 4), corresponding to an average actuarial recurrence rate 
of 8.5% per year.  Event-free survival rates on or off AADs were 91.1±2.4%, 83.0±3.2%, and 
70.4±4.2% at 1, 2, and 5 years of follow-up, respectively. Regression of AF was noted in 29 
(19.3%) patients: 14 (9.3%) patients maintained SR after re-initiation of AADs, and 15 (10.0%) 
patients presented only with paroxysmal recurrences. 
Factors associated with recurrent arrhythmias off AADs following the last ablation 
procedure are listed in Table 2. In multivariate analysis, independent predictors of recurrent 
arrhythmias were failure to terminate AF by ablation during the index procedure, structural heart 
GLVHDVHFRQWLQXRXV$)GXUDWLRQPRQWKVDQGDQ/$GLDPHWHUPP7DEOH)UHHGRP
from recurrent arrhythmias did not differ according to whether AF was terminated in the RA or 
LA (p=0.83).  Although the multiple-procedure success rate off AADs was lower in patients with 
long-standing persistent compared to persistent AF (55.1±5.6% vs. 77.8±6.8%; p=0.01; Figure 
5A), lack of AF termination during ablation was associated with a higher recurrence rate 
independent of whether AF was persistent or long-standing persistent (HR 3.831; 95%CI: 2.070-
7.143; p<0.0001). 
Arrhythmia-free survival rates after multiple procedures on or off AADs did not differ 
between patients who terminated to directly SR vs. to AT (83.1±7.8% vs. 80.0±4.8%; p=0.92), 
but were significantly reduced for patients in whom ablation failed to terminate AF (29.3±9.8%;
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p<0.0001; Figure 5B). 
Complications
Complications occurred in 4.4% of procedures (Pericardial effusion requiring intervention (n=6), 
phrenic nerve injury (n=3; full recovery during follow up), major femoral hematoma requiring 
intervention (n=2), cerebrovascular stroke (n=1; full recovery during follow up), myocardial 
infarction (n=1), and LA appendage isolation (n=1; no stroke during follow up)). There were no 
procedure-related deaths. Three deaths occurred over the course of follow-up (skin cancer (n=1); 
GI cancer (n=1); postoperative death after mitral valve replacement (n=1)). 
 During long-term follow-up, four patients suffered an ischemic stroke. Two of these 
patients had previously failed AF ablation and were on warfarin with sub-therapeutic INR levels 
at the time of stroke and had CHA2DS2VAScscores of 2 and 3, respectively. The third patient 
had previously failed AF ablation and was on therapeutic warfarin, with a CHA2DS2VASc score 
of 4. The fourth patient had been in SR during follow-up and was off warfarin, with a 
CHA2DS2VASc score of 0. AF was documented during the hospitalization for stroke 49 months 
after the last AF ablation procedure. All patients recovered without major residual impairment. 
Discussion  
Our study reveals several important findings. First, it confirms that termination of PsAF can be 
achieved in most patients using a stepwise ablation strategy. Second, by five years of follow-up, 
freedom from arrhythmia recurrence is modest with a single ablation procedure, but can be 
achieved in the majority of patients by repeat ablation as needed. Third, a slow but steady decline 
in freedom from arrhythmia recurrence is noted during long-term follow up, and predictors of 
DUUK\WKPLDUHFXUUHQFHLQFOXGHIDLOXUHWRWHUPLQDWH$)E\DEODWLRQDFRQWLQXRXV$)GXUDWLRQ
PRQWKVD/$GLDPHWHUPP, and structural heart disease.
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Long-term Outcome of Persistent AF Ablation
The concept of PVI as a treatment option for PAF is well established, with success rates of up to 
80% during long-term follow-up.1,3However, significantly less evidence exists for catheter 
ablation in PsAF patients.1,6Knowledge of the long-term outcome of PsAF ablation is paramount 
to define its role in clinical practice.A recent study reported the long-term clinical outcome 
undergoing catheter ablation of longstanding PsAF using circumferential PVI in all patients, plus 
additional substrate modification in limited patients.6 During 56 and 50 months follow-up, 
single- and multiple ablation procedure success was 20% and 45%, respectively. Circumferential 
PVI alone established long-term SR maintainance in only 24% of patients.6 These results raise 
the question whether circumferential PVI is the adequate ablation strategy for PsAF.
Haissaguerre et al. first described the stepwise ablation approach in PsAF.8,9 Using this 
approach, Rostock et al. reported a success rate of 79% after a median of 2.3 procedures with a 
median of 27 months of follow-up.13 Our study is the first to report on 5-year outcome in PsAF 
ablation aiming at AF termination as a procedural endpoint. To our knowledge, our study reports 
the highest long-term success rate in patients undergoing PsAF ablation. These results suggest 
that an ablation strategy beyond PVI may be of value in optimizing outcomes for PsAF. 
 However, the slow but steady decline in arrhythmia-free survival raises the question of 
whether ablation provides durable suppression of PsAF. Interestingly, arrhythmia recurred in 30 
SDWLHQWVZKRKDGPDLQWDLQHG65IRU\HDU. It may be speculated that some recurrences of AF 
escaped earlier detection and that amiodarone may have masked some AF drivers during the 
index procedure, which later became manifest.  These findings underscore the importance of 
careful long-term follow-up after AF ablation and have important ramifications regarding 
anticoagulation after PsAF ablation. 
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Impact of AF Termination
The other main finding of this study is that termination of PsAF by ablation can be achieved in 
the majority of patients and is the strongest predictor for freedom from arrhythmia recurrence 
during follow-up. Termination of AF may therefore represent a valid electrophysiological 
endpoint during PsAF ablation. 
 Reports dealing with the impact of AF termination on outcome are inconsistent. AF 
termination appeared to be a strong predictor of success in several studies.13,16 However, the rate 
of PsAF termination by ablation varies significantly between different approaches and centres. 
Although AF termination occurs in 16% of patients undergoing an anatomically guided 
circumferential PV ablation, 14termination rates of up to 87%are reported with the use of the 
stepwise ablation approach,8,11-13including ~20% of PsAF patients in whom PsAF is terminated 
during RA substrate modification.11,12
Clinical Implications
In the broad population of patients with PsAF, the optimal selection for and the strategy of 
catheter ablation has yet to be determined. Our study suggests that freedom from arrhythmia 
recurrence can be achieved in65% of patients over five years of follow up by ablation, and in 
74% when adding AADs. However, more than one ablation procedure is necessary in the 
majority of patients. In addition to patients’ symptoms, other characteristics such as continuous 
AF duration, presence of structural heart disease, or LA diameter should be used to decide with 
the patient if ablation is a viable treatment option. Procedural AF termination may predict 
favourable outcomes in patients undergoing substrate-based ablation. However, AF ablation in 
our study was associated with a significant procedural complication rate, consistent with the 
current world-wide experience with this procedure.1,22
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Limitations
The current study describes results from a single experienced centre including a limited number 
of patients. Due to the high AF termination rate reported in our study, which required long and 
arduous procedures, these results may not be generalizable to all ablation centers treating 
persistent AF. Furthermore, these results require confirmation in a randomized controlled trial 
comparing different PsAF ablation approaches.
Despite complying with recommendations regarding ECG monitoring for PsAF ablation1
with extensive efforts to detect asymptomatic recurrences, the potential for under-recognition of 
silent AF remains such that recurrence rates may have been underestimated.
Our study population represents a selected subgroup with persistent AF such that results 
should not be extrapolated to all patients with persistent AF.  
Finally, the optimal ablation strategy for persistent AF remains unknown such that less extensive 
and more focused procedures may potentially achieve similar long-term efficacy in the 
future.23,24
Conclusions
In PsAF patients, a stepwise catheter ablation strategy with AF termination as a procedural 
endpoint and with repeat interventions as needed provides acceptable freedom from arrhythmia 
recurrence over a 5-year follow up period. Procedural failure to terminate AF, PsAF duration 
PRQWKV/$GLDPHWHUPPDQGWKHSUHVHQFHRIVWUXFWXUDOKHDUWGLVHDVHDUHSUHGLFWRUVRI
arrhythmia recurrence. While most recurrences are observed during the first year, a slow but 
steady decline in arrhythmia-free survival is noted thereafter.
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Table 1: Baseline Characteristics (n = 150 patients)
Female gender 27 (18%) 
Age (years) 57 ± 10 
History of AF (months) 60 (36-120) 
Continuous AF duration (months) 13 (7-24) 
Long-standing persistent AF 97 (64.7%) 
Unsuccessful AADs (Class I & III) 2.1±1.0 
Amiodarone at time of procedure 32 (21.3%) 
LA diameter (mm) 48 ± 7 
LV ejection fraction (%) 58 ± 13 
Structural heart disease 64 (42.7%) 
Valvular heart disease 24 (16%) 
Dilated cardiomyopathy 22 (14.7%) 
Ischemic heart disease 20 (13.3%) 
Severe LV hypertrophy 12 (8%) 
Hypertension 64 (42.7%) 
Diabetes mellitus 13 (8.7%) 
Prior stroke or TIA  9 (6%)
CHADS2 score = 0 59 (39.3%) 
CHADS2 score = 1 54 (36%) 
CHADS2 VFRUH 37 (24.7%) 
Values are given as n (%), mean r SD, or median (25th-75th percentile). AF denotes atrial fibrillation; 
AADs, antiarrhythmic drugs; LA, left atrium; LV, left ventricle; TIA, transient ischemic attack.
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Table 2: Factors univariately associated with Arrhythmia Recurrence off Antiarrhythmic Drugs 
following the last Ablation Procedure 
Variable HR 95% CI P Value
Age, years 1.034 1.004 - 1.065 0.03
Continuous AF duration, months 1.021 1.015 - 1.027 <0.0001 
Diabetes mellitus 2.241 1.048 - 4.795 0.04
Structural heart disease 2.202 1.273 - 3.805 <0.01 
LA diameter, mm 1.059 1.010 - 1.111 0.02
Failure to terminate AF during 
first procedure 2.558 1.605-6.098 <0.001 
AF denotes atrial fibrillation; CI, confidence interval; HR, hazard ratio; LA, left atrium.
Table 3: Multivariate Predictors of Arrhythmia Recurrence off Antiarrhythmic Drugs following 
the last Ablation Procedure 
Variable HR 95% CI P Value
Failure to terminate AF during first procedure 3.831 2.070-7.143 <0.0001 
LA GLDPHWHUPP 2.083 1.078 - 4.016 0.03
&RQWLQXRXV$)GXUDWLRQPRQWKV 1.984 1.024 - 3.846 0.04
Structural heart disease 1.874 1.037 - 3.388 0.04
The final model consisted of the variables listed above along with age and diabetes mellitus, which were 
associated with P-values >0.05 and <0.1. AF denotes atrial fibrillation; CI, confidence interval; HR, 
hazard ratio; LA, left atrium.
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Figure Legends:
Figure 1: Procedural results of 150 patients undergoing their first AF ablation. AF = atrial 
fibrillation; AT = atrial tachycardia; DCC = electrical cardioversion; LA = left atrium; RA = 
right atrium; SR = sinus rhythm.
Figure 2: Single procedure success rate off antiarrhythmic drugs. Risk of arrhythmia recurrence 
was significantly higher in patients who did not terminate AFduring the intervention. 
Figure 3: Flowchart demonstrating arrhythmia outcome. AT = atrial tachycardia; PAF = 
paroxysmal AF; PsAF=persistent AF; SR = sinus rhythm.
Figure 4: Multiple procedure success rate off and on antiarrhythmic drugs of persistent AF 
ablation. During a median follow-up of 58 (IQR43-73) months following the last ablation 
procedure, 97 of 150 (64.7%) patients remained in SR without drugs.111 patients (74%) 
remained in SR when including patients taking antiarrhythmics.
Figure 5: Multiple procedure success rate off antiarrhythmic drugs according to whether AF was 
persistent or long-standing persistent (Panel A) and multiple procedure success rate on or off 
antiarrhythmic drugs according to whether AF terminated directly to sinus rhythm, AF
terminated to an atrial tachycardia, or AF did not terminate (Panel B). 
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
 
Electrophysiological Study and Ablation Procedure 
Details of the peri-procedural management and the ablation technique at our institution have 
been described previously.1-8  As it is standard clinical practice at our institution, all AADs were 
discontinued at least five half-lives prior to ablation except for amiodarone (n=32). All patients 
received oral anticoagulation (target INR 2–3) for ≥1 month prior to the procedure. Patients with 
a contraindication to warfarin or who refused oral anticoagulation were treated with anti-platelet 
agents, at their physician’s discretion. Patients underwent transesophageal echocardiography 
within 48h of the procedure to rule out thrombus. Warfarin was restarted the day after the 
procedure for ≥6 months after each ablation procedure and was continued thereafter at the 
physician’s discretion. 
The following catheters were introduced via the right femoral vein: (I) a deflectable 
quadripolar or decapolar catheter (2–5–2 mm electrode spacing, XtremTM, ELA MedicalTM, Le-
Plessis- Robinson, France) positioned within the coronary sinus; (II) a 10 pole, fixed-diameter 
circumferential mapping catheter to guide PVI (LassoTM; Biosense-WebsterTM, Diamond Bar, 
USA), introduced with the aid of a long sheath (PrefaceTM, Biosense-WebsterTM, Diamond Bar, 
USA, or SLOTM, St. Jude MedicalTM, St. Paul, USA); (III) a 3.5 mm irrigated-tip quadripolar 
ablation catheter (2–5–2 mm electrode spacing, ThermoCoolTM, Biosense-WebsterTM, Diamond 
Bar, USA). A single trans-septal puncture was performed in AP view with pressure monitoring.  
Stepwise ablation was performed in the following sequence: PVI, electrogram-based  
 2 
ablation, and linear ablation. The desired procedural endpoint was termination of AF without 
pharmacological or electrical cardioversion.  
Circumferential PVI was performed with the endpoint of abolition or dissociation of 
electrical activity of all PVs. When AF did not terminate during PVI, the procedure was 
continued with electrogram-based ablation in the LA. Ablation targets included all sites in the 
LA displaying any of the following electrogram features: continuous electric activity, complex 
rapid and fractionated potentials, sites with an activation gradient between electrograms of the 
proximal and distal bipoles of the ablation catheter, and sites with local short cycle lengths 
compared to the LA appendage. The endpoint of ablation in each region was transformation of 
complex into discrete electrograms and slowing of local cycle length compared with LA 
appendage or elimination of electrograms. The RF delivery was also stopped after 60 sec of 
application per site. 
When ablation of the inferior LA did not result in organization of the coronary sinus, 
additional ablation within the coronary sinus was performed, using the same electrogram-based 
criteria. Linear ablation was performed if AF persisted following the previous ablation steps. A 
roof line was performed joining the right and left superior PVs, and if AF continued, a mitral 
isthmus line from the mitral annulus to the left inferior PV was performed, with the endpoint of 
abolition of local electrograms.  
Mapping and ablation using the same electrogram-based criteria were continued in the 
right atrium (RA) if AF did not terminate during LA ablation and the RA appendage 
demonstrated a shorter cycle length than the LA appendage. Linear ablation was performed in all 
patients at the cavotricuspid isthmus either before or after restoration of SR and bidirectional 
conduction block was confirmed.  
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SUPPLEMENTAL FIGURE 
 
Supplemental Figure 1: Single procedure success rate off antiarrhythmic drugs. 
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